Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US5700466A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 2, 1994 |
| Grant date | Dec 23, 1997 |
| Priority date | — |
| Expiry date | Dec 2, 2014 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2400/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
RACTS, vol. 69, No. 2 (Jan. 15, 1980). Tracey, et al., 1986, "Shock and Tissue Injury Induced by . . . " Science 234: 470-474. Bentler, et al., 1985 "Passive Immunization Against Cachectin 1 tumor necrosis factor . . . " Science 229: 869-871. Bringman et al., 1987 "Monoclonal antibodies to human tumor necrosis factors . . . " Hybridoma 6(5): 489-507. Mc Namara, et al., 1984, "Monoclonal Idiotope Vaccine . . . " Science 220: 1325-1326. Fink, et al, 1990, "Laboratory models of Sepsis . . . " J. Surgical Res 49: 186-196. Verhoef, et al, 1990, "Prospects for monoclonal antibodies . . . " Eur. J. Clin. Microbiol. Infect. Dis. 9(4): 247-250. Fitzer-Schiller, 1993 "Centocor Stops trials of Flagship Drug"Wash. Post Jan. 18, 1993. Stone, 1993, "Biotec Industry Reels on Sepsis". LREP FRM Klauber & Jackson
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.